Skip to main content
HighTide Therapeutics, Inc. logo

HighTide Therapeutics, Inc. — Investor Relations & Filings

Ticker · 2511 HKEX Manufacturing
Open in API
Filings indexed 99 across all filing types
Latest filing 2025-03-14 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2511

About HighTide Therapeutics, Inc.

http://www.hightidetx.com

HighTide Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative, multifunctional, multi-targeted therapies. The company is dedicated to addressing unmet needs within the spectrum of inter-related chronic metabolic diseases, specifically emphasizing Cardiovascular-Kidney-Metabolic (CKM) conditions. HighTide's therapeutic strategy targets diseases driven by underlying mechanisms such as insulin resistance and chronic inflammation. The product pipeline includes five candidates covering nine indications in metabolic and digestive diseases. The lead candidate, HTD1801, is currently being advanced in chronic metabolic diseases, including MASH (Metabolic dysfunction-associated steatohepatitis), Type 2 Diabetes Mellitus (T2DM), Obesity, Primary Sclerosing Cholangitis (PSC), and Chronic Kidney Disease (CKD), utilizing its dual mechanism of action.

Recent filings

Filing Released Lang Actions
NOTICE OF DATE OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is a short announcement (1,364 characters) notifying shareholders of a future Board meeting date to consider and approve the audited annual results. It does not contain the actual annual report or detailed financial results, nor does it indicate management changes, dividends, share issues, or other specified categories. It is a Hong Kong Exchange announcement without substantive report content, fitting the fallback category for miscellaneous regulatory filings. Therefore, it should be classified as Regulatory Filings (RNS).
2025-03-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
Regulatory Filings Classification · 1% confidence The document is a HKEX FF301 monthly return under Chapter 19B of the Listing Rules, detailing movements in authorised share capital, issued shares, treasury shares and depositary receipts for the month ended 28 February 2025. It is a periodic regulatory compliance submission to the exchange, not an earnings release, proxy, or annual report. It does not announce a specific share issue event but reports routine capital movements. Therefore it best fits the fallback category “Regulatory Filings” (RNS).
2025-03-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
Share Issue/Capital Change Classification · 1% confidence The document is a standard monthly return (Form FF301) filed to the Hong Kong Stock Exchange detailing movements in authorised share capital, issued shares and treasury shares under Listing Rule Chapter 19B. It is not an earnings release, AGM material, or an annual/interim report. Instead, it specifically reports on share capital movements, which falls under the Share Issue/Capital Change category (SHA).
2025-02-03 English
HIGHTIDE COMPLETES PATIENT ENROLLMENT IN A HEAD-TO-HEAD PHASE III CLINICAL TRIAL EVALUATING HTD1801 VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Regulatory Filings Classification · 1% confidence The document is a voluntary business update announcement concerning completion of patient enrollment in a Phase III clinical trial. It contains no financial results, no notice of dividends, no management changes, no share transactions, no M&A, and no report publication or regulatory form references. It does not fit any specific category, so it falls under the fallback "Regulatory Filings" category (RNS).
2025-01-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
Regulatory Filings Classification · 1% confidence The document is a standard HKEX monthly return (Form FF301) filed under Chapter 19B of the Exchange Listing Rules, detailing movements in authorised share capital and issued/treasury shares for the month. It is a recurring regulatory filing rather than an earnings release, a management presentation, or an announcement of a specific report or transaction. It does not announce a new share issue or repurchase event but simply reports compliance under listing rules, fitting best into the general “Regulatory Filings” category (RNS).
2025-01-02 English
CHANGE OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Board/Management Information Classification · 1% confidence The document is a formal Hong Kong Exchange announcement detailing the resignation of one joint company secretary and the appointment of another, as well as a waiver from strict compliance with Listing Rules. This is a change in senior management (corporate secretary role) and pertains to governance matters. It is not a full annual or interim report, nor a dividend or earnings release, but an announcement of management changes. Therefore, it falls squarely under Board/Management Information (MANG).
2024-12-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.